← Back to all papers

The Cardiac Fuel Hypothesis: Heart Failure as a Metabolic State Problem

Framework Proposal Disclaimer: This is a framework proposal, not a peer-reviewed publication. Claims made here represent hypotheses to be tested. Published citations are referenced where available.

The Metabolic Crisis in Heart Failure

Heart failure is fundamentally a bioenergetic crisis. The failing heart shifts from efficient fatty acid oxidation (the normal cardiac fuel) to inefficient glycolysis, not as a pathologic change but as an emergency response. When this metabolic state is allowed to persist, it becomes self-perpetuating and worsens cardiac function.

This paper proposes that heart failure interventions fail or succeed based on whether they restore metabolic flexibility—the heart's capacity to use efficient fuels. Drugs that work in metabolically flexible hearts may harm metabolically rigid ones, and vice versa.

Normal Cardiac Metabolism

A healthy heart generates ATP primarily through fatty acid oxidation via mitochondrial oxidative phosphorylation. This pathway is highly efficient—complete oxidation of one fatty acid yields 30+ ATP molecules. The heart extracts nearly 70% of available oxygen, reflecting constant high metabolic demand.

Phosphocreatine serves as an energy buffer. The creatine kinase shuttle uses phosphocreatine to rapidly regenerate ATP during periods of high demand (systolic contraction), maintaining stable ATP levels beat-to-beat. In healthy hearts, the phosphocreatine-to-ATP ratio remains above 5, indicating abundant reserve capacity.

Metabolic flexibility is normal: the heart can shift toward glucose oxidation when glucose is abundant, or toward ketone and fatty acid oxidation when carbohydrates are scarce. This flexibility maintains efficient ATP production across varying metabolic conditions.

Metabolic Collapse in Heart Failure

A failing heart shows metabolic changes at every level:

The result: the heart runs on emergency generators, producing ATP slowly while burning through fuel rapidly. It cannot sustain the work demands of normal contraction. Ejection fraction declines. Pulmonary congestion develops.

PARAGON-HF and the Metabolic Threshold

PARAGON-HF tested sacubitril/valsartan in 4,822 heart failure patients with ejection fraction between 40-60%. The trial showed striking stratification by ejection fraction:

This threshold is not arbitrary. It marks the boundary where the metabolic state transitions from glycolytic crisis to metabolic preservation. Hearts with EF above 60% maintain fatty acid oxidation and intact metabolic flexibility. Hearts with EF below 57% are metabolically stressed and glucose-dependent.

The proposed mechanism: in metabolically preserved hearts, the drug has no metabolic advantage and may disrupt normal signaling. In metabolically failing hearts, the drug cannot restore metabolic flexibility, providing minimal benefit.

SGLT2 Inhibitors and Metabolic Restoration

SGLT2 inhibitors work through metabolic fuel shift, not hemodynamic improvement. The mechanism:

  1. SGLT2 inhibition blocks glucose reabsorption in the kidney, causing glucose wasting in urine
  2. The liver interprets this as "glucose is scarce" and upregulates hepatic ketogenesis
  3. Circulating ketone body levels rise moderately (0.3-1.5 mM with SGLT2i monotherapy)
  4. The heart shifts fuel preference from glucose toward ketones and fatty acids
  5. Metabolic flexibility is restored—the electron transport chain can process electrons from multiple sources without bottlenecking
  6. Phosphocreatine pools regenerate because ATP production becomes more efficient
  7. The creatine kinase shuttle resumes buffering ATP supply between heartbeats

This is direct metabolic restoration, not hemodynamic compensation. SGLT2 inhibitors work because they address the underlying metabolic problem in failing hearts.

The Role of Ketone Bodies

Ketone bodies (beta-hydroxybutyrate and acetoacetate) are uniquely valuable in the failing heart for several reasons:

Exogenous ketones (ketone esters or MCT oil) can achieve therapeutic concentrations (3-5 mM) within 30-60 minutes, providing acute metabolic repriming before chronic interventions take effect.

Metabolic Priming Hypothesis

The most metabolically compromised hearts—those with phosphocreatine depletion, severe lactate accumulation, and NAD+ exhaustion—may respond slowly to SGLT2 inhibitors alone. The proposed approach combines metabolic restoration with mechanistic intervention:

Phase 1: Metabolic Priming (Weeks 1-4)

Phase 2: Mechanistic Therapy (Week 5 onward)

The hypothesis: metabolic priming restores bioenergetic capacity, permitting the SGLT2 inhibitor to work more effectively and rapidly.

Supporting Evidence

Published trials of SGLT2 inhibitors show benefit in both reduced and preserved ejection fraction heart failure populations. This suggests SGLT2 inhibitors work by restoring metabolic function rather than through hemodynamic mechanisms alone. Early initiation of metabolic support might accelerate and enhance this response.

Testable Predictions

The metabolic hypothesis generates specific predictions:

Implications

If metabolic state is the fundamental problem in heart failure, then the therapeutic approach should address it directly: restore metabolic flexibility before or concurrent with mechanism-specific intervention. This reframes heart failure not as a structural problem requiring mechanical compensation but as a bioenergetic crisis requiring metabolic restoration.

References

Yurista et al. (2021). Ketone bodies for the failing heart: fuels that can fix the engine? Trends in Endocrinology and Metabolism, 32(10), 814-826.

Lopaschuk & Dyck (2023). Ketones and the cardiovascular system. Nature Cardiovascular Research, 2(5), 448-455.

Packer et al. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine, 383(15), 1413-1424.